Full Text
CASE 3 APPLICATION OF COST-EFFECTIVENESS ANALYSIS TO EVALUATE THE PROPOSED FORMULARY STATUS OF A NOVEL ANTIDIABETIC DRUG IN A U.S. COMMERCIAL HEALTH PLAN

Abstract

Authors

J Watkins M Minshall SD Sullivan

Back to Volume 10, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×